Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Polyethylene Glycol-Interferon Alfa-2B (PEG-Intron, SCH 54031) Compared to Interferon Alfa-2B in Participants With Chronic Hepatitis C (MK-4031-016)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Be serum positive for hepatitis C virus.~* Have liver biopsy within 1 year prior to entry, with a pathology report confirming a histological diagnosis consistent with chronic hepatitis.~* Have one abnormal historic ALT at least 6 months prior to screening, with elevated ALT at entry.~* Have compensated liver disease, testing negative for HIV and serum hepatitis B surface antigen (HBsAg) at entry.~* If male or female of childbearing potential, be practicing adequate contraception during treatment.~Exclusion Criteria:~* Be female who is currently pregnant or nursing.~* Have prior treatment with any interferon.~* Have suspected hypersensitivity to alpha interferon.~* Have participated in any other clinical trial within 30 days of entry~* Have received treatment with any investigational drug within 30 days of entry.~* Have received prior treatment for hepatitis with any other antiviral or immunomodulatory drug within the previous 2 years.~* Have any other cause for the liver disease other than chronic hepatitis C including but not limited to: co-infection with hepatitis B virus; Hemochromatosis; alpha-1 antitrypsin deficiency; Wilson's disease; autoimmune hepatitis; alcoholic liver disease; obesity-induced liver disease; and drug-related liver disease.~* Have hemophilia or any other condition that would prevent the participant from having a liver biopsy, including anticoagulant therapy.~* Have hemoglobinopathies (e.g., Thalassemia)~* Have evidence of advanced liver disease such as history or presence of ascites, bleeding varices, spontaneous encephalopathy.~* Have received organ transplants.~* Have a preexisting psychiatric condition, especially severe depression, or a history of severe psychiatric disorder, such as major psychoses, suicidal ideation and/or attempt.~* Have central nervous system trauma or active seizure disorders requiring medication.~* Have significant cardiovascular dysfunction within the past 6 months (e.g., angina, congestive heart failure, recent myocardial infarction, severe hypertension or significant arrhythmia).~* Have poorly controlled diabetes mellitus.~* Have chronic pulmonary disease (e.g., chronic obstructive pulmonary disease).~* Have immunologically mediated disease (e.g., inflammatory bowel disease \[Crohn's disease, ulcerative colitis\], rheumatoid arthritis, idiopathic thrombocytopenia purpura, systemic lupus erythematosus, autoimmune hemolytic anemia, scleroderma, severe psoriasis, clinical cryoglobulinemia with vasculitis).~* Have any medical condition requiring, or likely to require during the course of the study, chronic systemic administration of steroids.~* Have history of substance abuse, such as alcohol, intravenous drugs and inhaled drugs.~* Have clinically significant retinal abnormalities.~* Be unable to abstain from the consumption of alcohol.~* Have any other condition which in the opinion of the investigator would make the patient unsuitable for enrollment, or could interfere with the patient participating in and completing the protocol.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PEG-Intron, 0.5 mg/kg (Type: EXPERIMENTAL): PEG-Intron administered once weekly (QW) for 48 weeks at 0.5 mg/kg by subcutaneous (SC) injection.
- PEG-Intron, 1.0 mg/kg (Type: EXPERIMENTAL): PEG-Intron administered QW for 48 weeks at 1.0 mg/kg by SC injection.
- PEG-Intron, 1.5 mg/kg (Type: EXPERIMENTAL): PEG-Intron administered QW for 48 weeks at 1.5 mg/kg by SC injection.
- Interferon Alfa-2b (Type: ACTIVE_COMPARATOR): Interferon Alfa-2b administered three times per week (TIW) for 48 weeks at 3 million international units (MIU) by SC injection.

Based on this trial design, predict the completion outcome and termination type (if applicable).